National institute of biomedical imaging and bioengineering (nibib) innovation funnel coordination center for radx independent test assessment program for monkeypox
Ended Awarded Last action
- Contract number
- 75N92022F00003
- Awardee
-
The General Hospital Corporation UEI FLJ7DQKLL226
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $155,736
Award facts
- Opportunity
-
- 75N92022R0141 Solicitation number
- Contract value 100% obligated
- $155,735.58 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541614 Process, Physical Distribution, and Logistics Consulting Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Boston, MA 02114, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $155,736 |
About this award
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a no-cost extension delivery order to Massachusetts General Hospital (MGH), a renowned nonprofit academic medical center in Boston and teaching hospital of Harvard Medical School, for continuation of the Innovation Funnel Coordination Center supporting the RADx Independent Test Assessment Program for Monkeypox. The contract, valued at $155,735.58 under a firm fixed-price arrangement, extends through January 31, 2024. This award was issued without a set-aside designation, reflecting MGH's competitive positioning in the federal research marketplace. The underlying program supports the NIBIB's efforts to advance rapid, accurate, and accessible diagnostic testing capabilities for monkeypox detection and assessment.
The no-cost extension mechanism indicates that MGH will continue performing coordination and assessment activities under the existing delivery order terms without requiring additional federal funding beyond the previously obligated ceiling value. MGH's extensive track record as a major recipient of federal research funding from agencies including the National Institutes of Health and the Department of Defense, combined with its expertise in translational research spanning infectious diseases, advanced diagnostics, and biomedical innovation, positions the institution to effectively manage independent test assessment activities for the RADx program. This continuation supports NIBIB's broader mission to advance biomedical imaging and bioengineering solutions with critical public health applications.
Quick answers
Who was awarded contract 75N92022F00003?
75N92022F00003 was awarded to The General Hospital Corporation by National Heart Lung and Blood Institute (National Institutes of Health) on September 14, 2022.
How much is contract 75N92022F00003 worth?
The government has obligated $155,736 on 75N92022F00003.
Is contract 75N92022F00003 an order under another contract?
Yes. 75N92022F00003 is a delivery order under 75N92022D00014, an indefinite delivery contract.
Was contract 75N92022F00003 competed?
The extent of competition for 75N92022F00003 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award